Review
[Selegiline in Parkinson's disease; symptomatic or causal effect?]
[Article in
Dutch]
Affiliations
- PMID: 1528279
Item in Clipboard
Review
[Selegiline in Parkinson's disease; symptomatic or causal effect?]
[Article in
Dutch]
Ned Tijdschr Geneeskd.
.
Erratum in
- Ned Tijdschr Geneeskd 1992 Aug 22;136(34):1688
- Ned Tijdschr Geneeskd 1992 Dec 26;136(52):2600
- Ned Tijdschr Geneeskd 1992 Sep 5;136(36):1792
No abstract available
Similar articles
-
Does selegiline monotherapy in Parkinson's disease act by symptomatic or protective mechanisms?Neurology. 1992 Apr;42(4 Suppl 4):13-26; discussion 41-8. Neurology. 1992. PMID: 1584429 Review.
-
MAO-B inhibitors for the treatment of Parkinson's disease.Mov Disord. 2002;17 Suppl 4:S38-44. doi: 10.1002/mds.5559. Mov Disord. 2002. PMID: 12211138 Review. No abstract available.
-
Selegiline: a second look. Six years later: too risky in Parkinson's disease.Prescrire Int. 2002 Aug;11(60):108-11. Prescrire Int. 2002. PMID: 12199263
-
Monamine oxidase inhibitors: current and emerging agents for Parkinson disease.Clin Neuropharmacol. 2007 May-Jun;30(3):150-68. doi: 10.1097/01.wnf.0000240956.49315.be. Clin Neuropharmacol. 2007. PMID: 17545750 Review.
-
Selegiline for Parkinson's disease.Am Fam Physician. 1990 Feb;41(2):589-91. Am Fam Physician. 1990. PMID: 2105624 Clinical Trial.
Cited by
-
Vitamin E in extrapyramidal disorders.Pharm World Sci. 1993 Aug 20;15(4):146-50. doi: 10.1007/BF01880556. Pharm World Sci. 1993. PMID: 8220297 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical